Question explored with the scientific record
Is Rsv vaccines worth it for a healthy 72 year old
The short version: for a healthy 72-year-old, the RSV vaccine's benefit is real but modest, and the GBS risk is small but not zero.
The RSV vaccines cut RSV lung infections in older adults by roughly 66 to 83 percent and severe RSV by over 90 percent in trials [2], with real-world protection against hospitalization around 58 percent over two seasons [4]. But your absolute risk of a bad RSV outcome is low if you are healthy. RSV hits about 7 in 1,000 people over 65 per year [3], and the trials enrolled mostly people with coexisting conditions [4]. The trials were manufacturer-run, placebo-controlled, and used hard outcomes like hospitalization, which is better than antibody titers [1][4].
The safety signal that matters is Guillain-Barré syndrome, a nerve attack that causes weakness. A national English study found a real excess after the bivalent RSV vaccine in adults 74 to 79: about 23 extra GBS cases per million doses, with the risk concentrated in the first six weeks [5]. A separate US hospital-record analysis estimated about 11 extra GBS cases per million for all RSV vaccines, and about 18 per million for the Pfizer product [4]. That is rare, but it is a real harm, not a rumor.
| Measure | Number |
|---|---|
| RSV lung infection, yearly, age 65+ | 6.7 per 1,000 [3] |
| Vaccine efficacy vs RSV lung infection | 66-83% [2] |
| Real-world protection vs hospitalization, 2 seasons | 58% [4] |
| Extra GBS cases, England, age 74-79 | ~23 per million doses [5] |
| Extra GBS cases, US, all RSV vaccines | ~11 per million [4] |
My call: for a healthy 72-year-old with no heart or lung disease, the benefit is modest and the GBS risk is small but real, so this is a reasonable personal choice either way, not a clear must. Confidence: moderate.
Sources used 5
-
Efficacy of a Novel Nanoparticle RSV Vaccine in Preventing Infection in Older Adults: Phase III Clinical Trial
Nano-RSV, a liposome-encapsulated prefusion F protein nanoparticle RSV vaccine, reduces lab-confirmed RSV LRTI incidence and RSV-related hospitalizations in adults 60+ with a safety profile similar to placebo.
DOI: 10.54963/ti.v9i4.1004 -
THE ROLE OF RSV VACCINATION IN THE PREVENTION OF RESPIRATORY DISEASES IN OLDER ADULTS
RSV vaccination reduces lower respiratory tract infections, hospitalizations, and mortality in older adults; 2024 ACIP recommends a single dose for adults aged ≥75 or 60-74 with risk factors.
DOI: 10.31435/ijitss.1(49).2026.4899 -
From The First Breath to the Golden Years: Respiratory Syncytial Virus Prevention in Infants and Older Adults
This continuing-education article reviews the epidemiology, clinical presentation, risk factors, and newly available prevention options (subunit vaccines for older adults, maternal vaccination, and monoclonal antibodies for infants) for respiratory syncytial virus, emphasizing t…
DOI: 10.58931/cpct.2024.2127 -
Efficacy, effectiveness, and safety of respiratory syncytial virus vaccines in adults: Evidence from clinical trials and real-world effectiveness studies
Current RSV vaccines in adults ≥60 years show clinically meaningful trial efficacy and real-world effectiveness against RSV lower respiratory tract disease and hospitalization, with waning protection and small rare neurologic safety signals.
DOI: 10.12746/swjm.v14i60.1649 -
Assessing the risk of Guillain-Barré syndrome in older adults after bivalent RSV pre-F vaccination in England
A national vaccine-safety study in England found a small increased risk of Guillain-Barré syndrome after bivalent RSV pre-F vaccination in adults aged 74-79, with SCCS relative incidence 3.34 and about 23 attributable cases per million doses, outweighed by vaccine benefits.
DOI: 10.1038/s41467-025-66280-z